Acute urticarial rash after COVID-19 vaccination containing Polysorbate 80 [0.03%]
含有吐温80的COVID-19疫苗接种后出现急性荨麻疹样皮疹
Martina Burlando,Astrid Herzum,Emanuele Cozzani et al.
Martina Burlando et al.
We present the case of a 48-year-old Caucasian woman, who developed an acute urticarial rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Oxford-AstraZeneca. Though the most common cutaneous adverse reaction...
A case of acute encephalopathy and non-ST segment elevation myocardial infarction following mRNA-1273 vaccination: possible adverse effect? [0.03%]
mRNA-1273疫苗接种后出现急性脑病和非ST段抬高心肌梗死的一例报告：可能的不良反应？
Sabrina Yesmin Barsha,Miah Md Akiful Haque,Md Utba Rashid et al.
Sabrina Yesmin Barsha et al.
A 77-year-old man with a past medical history of type 2 diabetes mellitus, peripheral neuropathy, and chronic obstructive pulmonary disease was admitted to the intensive care unit of Bangladesh Medical College Hospital with acute encephalop...
Rujittika Mungmunpuntipantip,Viroj Wiwanitkit
Rujittika Mungmunpuntipantip
Challenges managing COVID vaccine-induced immune thrombotic thrombocytopenia in low-middle income countries [0.03%]
中低收入国家面临的挑战：管理COVID疫苗引起的免疫性血栓性血小板减少症
Céleo Ramírez,Ramón Jeremías Soto Hernández,Reyna M Durón
Céleo Ramírez
Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study [0.03%]
BNT162b2信使RNA冠状病毒病疫苗第一剂和第二剂接种后的反应原性：单中心研究
Yu Min Kang,Jaegyun Lim,Kang-Won Choe et al.
Yu Min Kang et al.
Purpose: This study was conducted to determine differences in adverse events associated with the first and second doses of the BNT162b2 coronavirus disease 2019 vaccine based on the age and sex of recipients. ...
Iffat Khanum,Lokesh Kumar,Safia Awan et al.
Iffat Khanum et al.
Purpose: Considering the cross-protection reported for bacillus Calmette-Guérin (BCG) vaccination on viral respiratory infections, it has been proposed that it could reduce the severity of coronavirus disease 2019 (COVID...
Post-vaccination COVID-19 deaths: a review of available evidence and recommendations for the global population [0.03%]
接种疫苗后发生的COVID-19死亡病例：现有证据的回顾及对全球人口的建议
Emmanuel Lamptey
Emmanuel Lamptey
Coronavirus disease 2019 (COVID-19) vaccines undergo rigorous testing in clinical trials to meet high safety standards before rollout to the general population. While over 200 million vaccines are administered in more than 50 countries, coi...
The effect of apolipoprotein A-I and perfluorocarbon emulsion on the production of specific antibodies in mice [0.03%]
载脂蛋白A-I和全氟碳乳剂对小鼠产生特异性抗体的影响
Vitaly Zhalimov,Yuliya Gritsyna,Oleg Morenkov
Vitaly Zhalimov
Adjuvants are often required to improve the potentially low immunogenicity of vaccines. In this study, it is proposed to use an emulsion based on fluorocarbons as an adjuvant. Since this emulsion adsorbs only a small range of proteins, apol...
Evaluation of the antigenic stability of influenza virus like particles after exposure to acidic or basic pH [0.03%]
酸或碱性pH处理后流感病毒样颗粒抗原稳定性的评价
So Hwa Kim,Young Chan Park,Jae Min Song
So Hwa Kim
Purpose: Virus-like particles (VLPs) are being developed as a promising vaccine platform and therapeutic delivery. Various strategies for effectively constructing VLPs have been studied, but relatively few studies have be...
Transient expression of fusion and hemagglutinin-neuraminidase epitopes of Newcastle disease virus in maize as a potent candidate vaccine [0.03%]
新城疫病毒融合和血凝素-神经氨酸酶表位在玉米中的瞬时表达作为一种潜在的疫苗候选者
Amir Ghaffar Shahriari,Ali Niazi,Maziar Habibi-Pirkoohi
Amir Ghaffar Shahriari
Purpose: Newcastle disease (ND) represents a major viral disease across the world which imposes high costs to poultry producers for vaccination. Hemagglutinin-neuraminidase (HN) and fusion (F) proteins are the major immun...